State harvest results official Xuan! Qilu, stone medicine to choose the lead.

Pharmaceutical Network August 21st, August 20th evening, Shanghai Sunshine Procurement Network officially announced the third batch of national drug centralized procurement to be selected results: 55 varieties have pharmaceutical companies to reduce prices should be tendered, only Ramif fixed flow mark.
, according to Xinhua News Agency, a total of 189 enterprises participated in the procurement, resulting in 125 enterprises to be selected, 191 products to be selected, the average price reduction of the products to be selected 53%.
According to the "Pharmaceutical Economics" reporter combed, compared with the highest effective declared price, the highest decline of a single variety of 98.72 percent, for the stone drug European-Italian hydrochloric acid tablets, and tofatib, Monrust sodium and non-nastamine and other six common varieties of the decline of more than 95%.
addition, the current round of harvesting has again produced three "one penny" varieties, namely, Catopri, metformin and chlorine nitrogen.
from the specific enterprise bid situation, most of the original pharmaceutical companies still maintain a cautious attitude to choose "retreat", only Weiss, Pfizer and Anbisheng three foreign companies to participate.
, Pfizer and Wesai both exchanged more than 70% of the price reduction for the first-place finish of the Lyne amine tablets and methylcobalamin tablets, respectively.
While the competition for the remaining varieties is basically the carnival of the leading local pharmaceutical companies, Qilu and Shi medicine both won 8 varieties, the largest number of bidding enterprises, while Yangzijiang and Howson followed closely behind, respectively, to obtain 7 and 5 varieties of the bid qualification, Haizheng and Hengrui are 4 respectively.
metformin and other drugs to break through the floor price of metformin is undoubtedly the most competitive varieties in this round of collection, according to statistical estimates, its oral regular release agent type of the amount of up to 4.66 billion tablets, accounting for 23.3% of the overall report.
as the largest number of 56 varieties of products reported at the same time, metformin oral regular release dosage form also has as many as 28 pharmaceutical companies with declared qualifications to come to compete.
After a white-hot price competition, Beijing Jingfeng, Shanghai Xinyi and Shi Medicine Europe and other eight pharmaceutical companies to obtain the proposed winning ticket, of which Chongqing Corey is to reduce the price of metformin tablets to "one-fifth" of the floor price.
drug companies are also focusing on the highest purchase of moxiza star sodium chloride injections, the purchase amount of the single product in the current round of up to 1.76 billion yuan, accounting for 7.8% of the total procurement.
meters intranet data show that in 2019, China's public medical institutions terminal, Moxisa star sodium chloride injection of the original research drug company Bayer market share of 93.82 percent, leaving Tianjin Red Day and Hainan Aicco two over-evaluated pharmaceutical companies market share of less than 10 percent.
, the competitive landscape for sodium chloride injections in Moxiza is about to be rewritten, with two local drug companies winning half of the country's market share at prices of more than 80%.
And the only flow target of Ramifding, is the current round of national collection and procurement of the smallest amount of varieties, only 170,000 yuan, only 7.5 parts of the total procurement amount, which may also be one of the important reasons for the flow of the species.
It is worth noting that in the price ofacid sidna non-price competition, Qilu Pharmaceuticals became the only winning enterprise of the variety, which is also the only one in this round of collection appeared in the exclusive winning variety.
it is understood that Qilu Pharmaceuticals' Sidnaf has only been approved for listing on August 7th, as if through the identity of the conformity evaluation of the last bus, will get 40% of the country's procurement volume.
the withdrawal of foreign enterprises and "pushing forward" in the face of the situation such as bamboo national mining, the original research and pharmaceutical enterprises are showing the "ice fire two days" attitude.
the number of varieties is at a new high, the number of original pharmaceutical companies involved in this collection is not in the minority.
statistics, Pfizer and Merca East involve 5 varieties, Novarma, AstraZenetel, Lilly and Yoshibi involve 3 varieties, and Astellas and BMS involve 2 varieties.
Of these varieties, Pfizer's Celexib, Tofatibu, Novarma's Viglitin, Xinji's Aza cytosine, Mercedon's Reliance Cossy and so on occupy almost all of the market share, and other original research varieties also account for almost half of the market share.
However, many foreign-owned varieties are out early because of overbidding (above the limit), including AstraZeneca's Anatrobe, Lilly's Onazole, Mercado's Dechloretatin, Xi'an Jansen's Dopanlitone, Roche's Carpenter, GSK's Ramifding, Pfizer's Sherwood, Xi'an Jansen's Priscilla.
the end, only Weisai (China) Pharmaceuticals methyl cobalt tablets won the bid in 1st place, a decrease of about 76% compared to the limit price; Bisheng Pharmaceutical Tansorosin slow release capsule with the 4th position, a decrease of about 56%, Hangzhou Minsheng Riverside Pharmaceutical Agent Anbisheng Menglust sodium chewing tablets with the 3rd shunned bid, a price reduction of about 91%.
can be said that in addition to the "hit Pfizer" caused concern in the industry, other original drug companies more silently hidden in this round of "price reduction tide" behind.
fact, at the beginning of this year Bayer A capo sugar quoted as low as 0.1 yuan, nearly 80% lower than the limit price.
However, as can be seen from Bayer's 2020 half-yearly report, Acapo sugar sales fell sharply under the influence of the harvest, with revenues of 4 billion euros in the second quarter of this year, down about 74% year-on-year, and half-year sales of 15.6 billion euros, down 54.4% year-on-year.
and sales of some of the failed multinational drug companies have bucked the trend.
, the industry has speculated that multinational pharmaceutical companies may no longer be actively involved in volume procurement.
results, the original manufacturer's quotation strategy is quite "conservative".
the game began to convercede in the industry's view, Qumeita pyridehye tablets 8 cents, Catopri 1 cent, metformin reported to 1 cent ... Such quotations can never be described in terms of cost.
Some industry experts pointed out that from the quotation to see the market access level of each pharmaceutical company is uneven, some pharmaceutical companies are well prepared, including the product's own manufacturing costs and full cost measurement, product line cost measurement, the two-and-a-half rounds of the law has been carried out to explore, the evaluation of competitors and quotation strategies.
, according to the new medical insurance balance incentive mechanism set up in this round, the unseeded products will basically withdraw from the hospital market.
industry had also expected that the collection of drug prices kill or more intense, a substantial reduction in price into the inevitable choice of enterprises.
this round of collection quotes is still more intense than the industry expected.
at the same time, the variance of quotations between enterprises is also narrowing, excluding some "dot kill" situation, the difference between quotations of multiple varieties of enterprises is about 10%.
e.g. ibuprofen slow release capsules, azatrol, dopamine tablets, methylcobalamin tablets and other varieties, the selected enterprise quotations are mostly concentrated in the limit price of 60% to 10% range, which indicates that the enterprise's expectations of the collection price is similar, the method of calculating costs is not much different.
industry pointed out that in the next two years or so, the focus areas of large varieties will be adopted.
the evaluation of the winning bid will rob the market without the winning bid, the evaluation of the product will rob the market without evaluation.
another three years or so, the same treatment field has been evaluation of hopeless generic drugs, will gradually accept the market is eaten up situation.
called for support for companies actively engaged in consistency evaluation.
.